Sourcing & Management of Health Products

The Global Fund / Karin Schermbrucker

Opportunity for Evaluation of Selected Medicines

26 August 2019

The Global Fund, Stop TB Partnership Global Drug Facility and Unitaid are inviting manufacturers of antiretroviral (HIV/AIDS), antihepatitis B and C, antituberculosis and antimalarial medicines to submit an expression of interest to have their products evaluated by the Expert Review Panel for Pharmaceutical Products.

Detailed information about the review process and submission requirements for this Round 21 opportunity can be found in the document below.

Once all expressions of interest have been received, the Expert Review Panel will be responsible for reviewing and judging their eligibility and whether to perform a risk-benefit assessment of the products submitted.

The deadline for submission of an expression of interest is Friday, 18 October 2019 (COB). By the end of October 2019, the Global Fund Secretariat will communicate to manufacturers the outcomes of the review of the completeness of the documents submitted. The results of the product evaluations are expected to be released the end of December 2019.

  • Invitation to Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial Medicines Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical Products
    download in English
  • Timeline of the Expert Review Panel Process for Pharmaceutical Products
    download in English